Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome Inc.’s Chief Business Officer Kinney Horn reported option exercises and related stock sales. On August 4, 2026, Horn exercised employee stock options for an aggregate 90,616 shares of common stock at exercise prices of $12.92 and $10.60 per share, then reported selling 90,616 shares of common stock at a weighted average price of $25.09 per share, within a range of $25.00–$25.295, pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
IMNM shareholder ABHMC II LLC, through Merrill Lynch, plans to sell 108,504 shares of common stock on or after August 6, 2026 on Nasdaq. The shares were acquired from the issuer in a private placement on October 3, 2023 for cash. The issuer reports 113,250,394 shares outstanding of this class.
Over the past three months, ABHMC II LLC has sold multiple IMNM common stock blocks, including 100,000 shares on June 30, 2026, 100,000 shares on July 2, 2026, and additional smaller trades through July 7, 2026. ARSENAL BRIDGE VENTURE II-B LLC also sold 1,050 shares on June 30, 2026.
Alfred K. Horn submitted a notice to sell up to 90,616 shares of IMNM common stock through Fidelity Brokerage Services LLC on 08/04/2026 in connection with a stock option exercise. During the prior three months, he sold 1,092 shares of common stock for an aggregate amount of 27,300.00 on 07/07/2026.
Immunome Inc.’s Chief Business Officer, Kinney Horn, received equity compensation awards. On July 23, 2026, Horn was granted 31,250 shares of common stock underlying RSUs and 62,500 employee stock options with a $22.01 exercise price, vesting over time subject to continuous service, with options expiring July 22, 2036.
Immunome Inc. reported equity awards to Chief Technical Officer Philip Tsai on July 23, 2026. Tsai received 76,500 stock options at a $22.01 exercise price expiring in 2036 and 38,250 RSUs, all vesting over time contingent on his continuous service, bringing reported direct holdings to 81,550 common shares/RSUs.
Immunome Inc. reported equity awards to its Chief Legal Officer and General Counsel, Sandra G. Stoneman. On July 23, 2026 she received stock options for 76,500 shares at a $22.01 exercise price, expiring July 22, 2036, plus 38,250 RSUs. The RSUs vest 25% annually on each grant-date anniversary, and the options vest 25% on July 23, 2027 with the balance vesting monthly over three years, in each case subject to continued service. Following the RSU award she directly holds 43,805 shares or RSUs of common stock.
Higgins Jack reported acquisition or exercise transactions in this Form 4 filing.
Immunome Inc. granted Chief Scientific Officer Jack Higgins 76,500 employee stock options to buy Common Stock at $22.01 per share, expiring in 2036, and 38,250 RSU-based Common Stock awards on 2026-07-23. Both the options and RSUs vest over time, subject to continuous service, and Higgins also reports indirect custodial holdings of 1,000 shares for each of three children, for which beneficial ownership is disclaimed.
Immunome Inc. Chief Financial Officer Max Rosett received equity awards of 94,500 employee stock options and 47,250 restricted stock units on July 23, 2026.
The options have a $22.01 exercise price, expire July 22, 2036, and vest 25% on July 23, 2027 with the remainder vesting monthly. The RSUs vest 25% annually on each grant anniversary; after the RSU grant he held 101,287 common shares directly and 94,500 options.
Immunome Inc. granted Chief Medical Officer Robert Lechleider 54,000 RSUs and an employee stock option for 108,000 shares at a $22.01 exercise price on 2026-07-23. The RSUs vest 25% annually, while the options vest 25% on July 23, 2027 and monthly thereafter. After these awards he directly holds 69,805 common shares and 108,000 options.
Immunome Inc. granted equity awards to President and CEO Clay B. Siegall on July 23, 2026. He received 180,000 RSUs, with 25% vesting on each anniversary of the grant date, and 360,000 stock options with a $22.01 exercise price, 25% vesting on July 23, 2027 and the remainder in equal monthly installments thereafter, all subject to continued service. Following the RSU grant, he directly holds 870,704 common shares, in addition to the newly granted options.